Mineralys Therapeutics Approves Key Proposals at Annual Meeting

Mineralys Therapeutics, Inc. ( (MLYS) ) has provided an announcement.

On May 22, 2025, Mineralys Therapeutics, Inc. held its annual meeting of stockholders, where two key proposals were approved. The first proposal involved the election of two directors, Glenn P. Sblendorio and Derek DiRocco, Ph.D., to serve as Class II directors for a three-year term. The second proposal ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. These approvals reflect shareholder confidence and are expected to support the company’s strategic direction and financial oversight.

The most recent analyst rating on (MLYS) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.

Spark’s Take on MLYS Stock

According to Spark, TipRanks’ AI Analyst, MLYS is a Neutral.

Mineralys Therapeutics shows promise with positive clinical trial results and a strong cash position, but faces challenges with continuous losses and negative cash flows. Technical analysis suggests short-term momentum, while valuation remains a concern due to lack of revenue. The earnings call highlighted upcoming milestones that could enhance future prospects.

To see Spark’s full report on MLYS stock, click here.

More about Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapeutic solutions.

Average Trading Volume: 1,294,679

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.05B

Find detailed analytics on MLYS stock on TipRanks’ Stock Analysis page.